Description: AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Home Page: www.astrazeneca.com
1 Francis Crick Avenue
Cambridge,
CB2 0AA
United Kingdom
Phone:
44 20 3749 5000
Officers
| Name | Title |
|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Executive Director |
| Dr. Aradhana Sarin M.D. | CFO & Executive Director |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
| Mr. Andrew P. Barnett | Head of Investor Relations |
| Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board |
| Gonzalo Vina | Head of Global Media Relations |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research & Development |
| Mr. Leon Wang | Executive VP of International & China President |
| Ms. Iskra Reic | Executive Vice-President of Vaccines & Immune Therapies |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 14.5985 |
|---|---|
| Trailing PE: | 32.9209 |
| Price-to-Book MRQ: | 5.201 |
| Price-to-Sales TTM: | 3.9071 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 89900 |